secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001104659-25-025559
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics FY2024 net loss $126.6M; discontinues ELiPSE-1, focuses on CNTY-308
--------------------------------------------------------------------------------

- Net loss $126.6M for FY2024 ($136.7M in 2023); cash $220.1M, runway into Q4 2026.
- Discontinued ELiPSE-1 Phase 1 trial for CNTY-101 in R/R NHL; data not transformational.
- Pipeline re-prioritized to four programs led by CNTY-308 (CD19 CAR-iT); IND-enabling studies mid-2025.
- First patient dosed in CALiPSO-1 Phase 1 trial for CNTY-101 in autoimmunity; CARAMEL IIT to start mid-2025.
- Collaboration revenue from BMS $6.6M; R&D expenses $107.2M (up from $92.7M) driven by trial and manufacturing costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/0001104659-25-025559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925025559/tm259654d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer